BioCentury | Oct 13, 2017
Emerging Company Profile

CBT’s silk road

...developing novel compounds for the China market, but that do not have an ex-China strategy. Huya Bioscience International LLC...
...also developing China-sourced therapeutics outside of China, but for cardiovascular disease as well as cancer. Huya...
...Calif. Crown Bioscience International Inc. (TPEx:6554), Taipei, Taiwan Galena Biopharma Inc. (NASDAQ:GALE), San Ramon, Calif. Huya...
BioCentury | Aug 25, 2016
Strategy

Mixed bag for PPPs

...variety of companies. As a group, top PPP-producing biotech companies such as Evotec AG and Huya Bioscience International LLC...
...Calif. Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Horizon Discovery Group plc (LSE:HZD), Cambridge, U.K. Huya Bioscience International LLC...
BioCentury | Apr 13, 2016
Company News

Management tracks

...the cardiovascular center of excellence at Quintiles Transnational Holdings Inc. (NYSE:Q). Sharp was CFO at Huya Bioscience International LLC...
BioCentury | Mar 28, 2016
Company News

Fudan University, Huya deal

...The university granted Huya exclusive, ex-Chinese rights to undisclosed immuno-oncology compounds that inhibit indoleamine 2,3-dioxygenase (INDO...
...2,3-dioxygenase (INDO; IDO). The partners did not respond to inquiries. Fudan University , Shanghai, China Huya Bioscience International LLC...
BioCentury | Mar 24, 2016
Company News

Management tracks

Huya Bioscience International LLC (San Diego, Calif.), which is developing oncology and cardiovascular candidates sourced in China, named John Ratliff president and CEO. He replaces founder and CEO Mireille Gillings, who will continue as executive...
BioCentury | Feb 8, 2016
Company News

Huya, Eisai deal

...for cancer indications in Japan, South Korea, Thailand, Malaysia, Indonesia, the Philippines, Vietnam and Singapore. Huya...
...non-Hodgkin’s lymphoma (NHL) in Japan, and Eisai will develop the product for solid tumor indications. Huya...
...and Taiwan to treat cancer. Gold NanoTech Inc. (Taipei, Taiwan) holds exclusive rights in Taiwan. Huya...
BioCentury | Feb 2, 2016
Company News

Huya, Eisai strike deal for Chipscreen drug

...Diego, Calif.) granted Eisai Co. Ltd. (Tokyo:4523) exclusive rights to HBI-8000 in several Asian territories. Huya...
...in China as Epidaza chidamide to treat relapsed or refractory peripheral T cell lymphoma (PTCL). Huya...
...and Singapore. Huya is eligible for $280 million in upfront and milestone payments, plus royalties. Huya...
BioCentury | Jun 17, 2015
Company News

Management tracks

...EVP, COO and co-founder of Hip Innovation Technology LLC (Plantation, Fla.). Oncology and cardiovascular play Huya Bioscience International LLC...
BioCentury | Mar 13, 2015
Company News

Management tracks

Huya Bioscience International LLC (San Diego, Calif.), which is developing oncology and cardiovascular candidates sourced in China, appointed Alain Rolland EVP and CSO. Rolland was most recently EVP of product development at Vical Inc. (NASDAQ:VICL)....
BioCentury | Feb 9, 2015
Clinical News

Epidaza chidamide regulatory update

...Gold NanoTech has exclusive rights to the small molecule histone deacetylase (HDAC) inhibitor in Taiwan. Huya...
...Chipscreen to the compound outside of China and Taiwan. Gold NanoTech Inc. , Taipei, Taiwan Huya Bioscience International LLC...
Items per page:
1 - 10 of 43
BioCentury | Oct 13, 2017
Emerging Company Profile

CBT’s silk road

...developing novel compounds for the China market, but that do not have an ex-China strategy. Huya Bioscience International LLC...
...also developing China-sourced therapeutics outside of China, but for cardiovascular disease as well as cancer. Huya...
...Calif. Crown Bioscience International Inc. (TPEx:6554), Taipei, Taiwan Galena Biopharma Inc. (NASDAQ:GALE), San Ramon, Calif. Huya...
BioCentury | Aug 25, 2016
Strategy

Mixed bag for PPPs

...variety of companies. As a group, top PPP-producing biotech companies such as Evotec AG and Huya Bioscience International LLC...
...Calif. Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Horizon Discovery Group plc (LSE:HZD), Cambridge, U.K. Huya Bioscience International LLC...
BioCentury | Apr 13, 2016
Company News

Management tracks

...the cardiovascular center of excellence at Quintiles Transnational Holdings Inc. (NYSE:Q). Sharp was CFO at Huya Bioscience International LLC...
BioCentury | Mar 28, 2016
Company News

Fudan University, Huya deal

...The university granted Huya exclusive, ex-Chinese rights to undisclosed immuno-oncology compounds that inhibit indoleamine 2,3-dioxygenase (INDO...
...2,3-dioxygenase (INDO; IDO). The partners did not respond to inquiries. Fudan University , Shanghai, China Huya Bioscience International LLC...
BioCentury | Mar 24, 2016
Company News

Management tracks

Huya Bioscience International LLC (San Diego, Calif.), which is developing oncology and cardiovascular candidates sourced in China, named John Ratliff president and CEO. He replaces founder and CEO Mireille Gillings, who will continue as executive...
BioCentury | Feb 8, 2016
Company News

Huya, Eisai deal

...for cancer indications in Japan, South Korea, Thailand, Malaysia, Indonesia, the Philippines, Vietnam and Singapore. Huya...
...non-Hodgkin’s lymphoma (NHL) in Japan, and Eisai will develop the product for solid tumor indications. Huya...
...and Taiwan to treat cancer. Gold NanoTech Inc. (Taipei, Taiwan) holds exclusive rights in Taiwan. Huya...
BioCentury | Feb 2, 2016
Company News

Huya, Eisai strike deal for Chipscreen drug

...Diego, Calif.) granted Eisai Co. Ltd. (Tokyo:4523) exclusive rights to HBI-8000 in several Asian territories. Huya...
...in China as Epidaza chidamide to treat relapsed or refractory peripheral T cell lymphoma (PTCL). Huya...
...and Singapore. Huya is eligible for $280 million in upfront and milestone payments, plus royalties. Huya...
BioCentury | Jun 17, 2015
Company News

Management tracks

...EVP, COO and co-founder of Hip Innovation Technology LLC (Plantation, Fla.). Oncology and cardiovascular play Huya Bioscience International LLC...
BioCentury | Mar 13, 2015
Company News

Management tracks

Huya Bioscience International LLC (San Diego, Calif.), which is developing oncology and cardiovascular candidates sourced in China, appointed Alain Rolland EVP and CSO. Rolland was most recently EVP of product development at Vical Inc. (NASDAQ:VICL)....
BioCentury | Feb 9, 2015
Clinical News

Epidaza chidamide regulatory update

...Gold NanoTech has exclusive rights to the small molecule histone deacetylase (HDAC) inhibitor in Taiwan. Huya...
...Chipscreen to the compound outside of China and Taiwan. Gold NanoTech Inc. , Taipei, Taiwan Huya Bioscience International LLC...
Items per page:
1 - 10 of 43